Literature DB >> 17182759

Vancomycin-resistant Enterococcus faecalis endocarditis: linezolid failure and strain characterization of virulence factors.

Constantine Tsigrelis1, Kavindra V Singh, Thais D Coutinho, Barbara E Murray, Larry M Baddour.   

Abstract

Infective endocarditis due to vancomycin-resistant (VR) Enterococcus faecalis has only rarely been reported. We report a case of VR E. faecalis endocarditis that failed to respond to linezolid therapy, outline the virulence traits of the isolate, and review previously published cases of VR E. faecalis endocarditis.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17182759      PMCID： PMC1829077          DOI： 10.1128/JCM.02188-06

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  36 in total

1.  A case of vancomycin-resistant enterococcal endocarditis.

Authors:  A J Brink; J van den Ende; R J Routier; L Devenish
Journal:  S Afr Med J       Date:  2000-11

2.  Role of mobile DNA in the evolution of vancomycin-resistant Enterococcus faecalis.

Authors:  I T Paulsen; L Banerjei; G S A Myers; K E Nelson; R Seshadri; T D Read; D E Fouts; J A Eisen; S R Gill; J F Heidelberg; H Tettelin; R J Dodson; L Umayam; L Brinkac; M Beanan; S Daugherty; R T DeBoy; S Durkin; J Kolonay; R Madupu; W Nelson; J Vamathevan; B Tran; J Upton; T Hansen; J Shetty; H Khouri; T Utterback; D Radune; K A Ketchum; B A Dougherty; C M Fraser
Journal:  Science       Date:  2003-03-28       Impact factor: 47.728

3.  Modulation of virulence within a pathogenicity island in vancomycin-resistant Enterococcus faecalis.

Authors:  Nathan Shankar; Arto S Baghdayan; Michael S Gilmore
Journal:  Nature       Date:  2002-06-13       Impact factor: 49.962

4.  Distribution of fsr among Enterococcus faecalis isolates from the SENTRY antimicrobial surveillance program.

Authors:  Ronald N Jones; Lalitagauri M Deshpande
Journal:  J Clin Microbiol       Date:  2003-08       Impact factor: 5.948

5.  The enterococcal surface protein, Esp, is involved in Enterococcus faecalis biofilm formation.

Authors:  A Toledo-Arana; J Valle; C Solano; M J Arrizubieta; C Cucarella; M Lamata; B Amorena; J Leiva; J R Penadés; I Lasa
Journal:  Appl Environ Microbiol       Date:  2001-10       Impact factor: 4.792

Review 6.  Prosthetic biologic valve endocarditis caused by a vancomycin-resistant (vanA) Enterococcus faecalis: case report.

Authors:  P Carfagna; A Tarasi; M Cassone; M F Del Grosso; G Bianco; M Venditti
Journal:  J Chemother       Date:  2000-10       Impact factor: 1.714

7.  Virulence effect of Enterococcus faecalis protease genes and the quorum-sensing locus fsr in Caenorhabditis elegans and mice.

Authors:  Costi D Sifri; Eleftherios Mylonakis; Kavindra V Singh; Xiang Qin; Danielle A Garsin; Barbara E Murray; Frederick M Ausubel; Stephen B Calderwood
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

8.  Molecular epidemiology of the fsr locus and of gelatinase production among different subsets of Enterococcus faecalis isolates.

Authors:  Jill C Roberts; Kavindra V Singh; Pablo C Okhuysen; Barbara E Murray
Journal:  J Clin Microbiol       Date:  2004-05       Impact factor: 5.948

9.  Putative surface proteins encoded within a novel transferable locus confer a high-biofilm phenotype to Enterococcus faecalis.

Authors:  Preeti M Tendolkar; Arto S Baghdayan; Nathan Shankar
Journal:  J Bacteriol       Date:  2006-03       Impact factor: 3.490

10.  Prevalence of the fsr locus in Enterococcus faecalis infections.

Authors:  S K Pillai; G Sakoulas; H S Gold; C Wennersten; G M Eliopoulos; R C Moellering; R T Inouye
Journal:  J Clin Microbiol       Date:  2002-07       Impact factor: 5.948
View more
  9 in total

1.  Enterococcal endocarditis: can we win the war?

Authors:  Jose M Munita; Cesar A Arias; Barbara E Murray
Journal:  Curr Infect Dis Rep       Date:  2012-08       Impact factor: 3.725

Review 2.  Management of multidrug-resistant enterococcal infections.

Authors:  C A Arias; G A Contreras; B E Murray
Journal:  Clin Microbiol Infect       Date:  2010-06       Impact factor: 8.067

3.  Newly discovered and characterized antivirulence compounds inhibit bacterial mono-ADP-ribosyltransferase toxins.

Authors:  Zachari Turgeon; René Jørgensen; Danielle Visschedyk; Patrick R Edwards; Sarah Legree; Caroline McGregor; Robert J Fieldhouse; Dev Mangroo; Matthieu Schapira; A Rod Merrill
Journal:  Antimicrob Agents Chemother       Date:  2010-12-06       Impact factor: 5.191

4.  A trilocus sequence typing scheme for hospital epidemiology and subspecies differentiation of an important nosocomial pathogen, Enterococcus faecalis.

Authors:  Shahreen A Chowdhury; Cesar A Arias; Sreedhar R Nallapareddy; Jinnethe Reyes; Rob J L Willems; Barbara E Murray
Journal:  J Clin Microbiol       Date:  2009-07-01       Impact factor: 5.948

5.  What's New in the Treatment of Enterococcal Endocarditis?

Authors:  Masayuki Nigo; Jose M Munita; Cesar A Arias; Barbara E Murray
Journal:  Curr Infect Dis Rep       Date:  2014-10       Impact factor: 3.725

6.  Clinical update on linezolid in the treatment of Gram-positive bacterial infections.

Authors:  Sally Ager; Kate Gould
Journal:  Infect Drug Resist       Date:  2012-06-25       Impact factor: 4.003

7.  Porcine and human community reservoirs of Enterococcus faecalis, Denmark.

Authors:  Jesper Larsen; Henrik C Schønheyder; Kavindra V Singh; Camilla H Lester; Stefan S Olsen; Lone J Porsbo; Lourdes Garcia-Migura; Lars B Jensen; Magne Bisgaard; Barbara E Murray; Anette M Hammerum
Journal:  Emerg Infect Dis       Date:  2011-12       Impact factor: 6.883

Review 8.  Current Evidence on Oral Antibiotics for Infective Endocarditis: A Narrative Review.

Authors:  Takaaki Kobayashi; Tomo Ando; Judy Streit; Poorani Sekar
Journal:  Cardiol Ther       Date:  2019-09-18

Review 9.  Vancomycin-resistant enterococcal infections: epidemiology, clinical manifestations, and optimal management.

Authors:  Tristan O'Driscoll; Christopher W Crank
Journal:  Infect Drug Resist       Date:  2015-07-24       Impact factor: 4.003
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.